MEOBF (Mesoblast) Net Margin %: 0.00% (As of Dec. 2025)


MEOBF Mesoblast Ltd MEOBF
47 GF Score
Price $1.55
! 4 Warning Signs
View Full Analysis

What is Mesoblast Net Margin %?

Mesoblast MEOBF 47 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates MEOBF with a GF Score™ of 47/100. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Mesoblast ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Mesoblast's Net Income for the three months ended in Dec. 2025 was $0.00 Mil. Mesoblast's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Mesoblast's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Mesoblast's Net Margin % or its related term are showing as below:


MEOBF's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Mesoblast  (OTCPK:MEOBF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Mesoblast Net Margin % Related Terms

Mesoblast Net Margin % Historical Data

* Premium members only.

The historical data trend for Mesoblast's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Net Margin % Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,329.18 -894.59 -1,091.71 -1,490.27 -593.92

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEOBF vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Mesoblast's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mesoblast's Net Margin % falls into.


MEOBF
47GF Score
Mesoblast Ltd MEOBF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mesoblast's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-102.142/17.198
=-593.92 %

Mesoblast's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Mesoblast (MEOBF) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Mesoblast and its competitors. According to the industry distribution chart, Mesoblast ranks #999999 out of 947 companies in the Biotechnology industry.
Is Mesoblast's Net Margin % too high?
Mesoblast's current Net Margin % is 0.00%. Based on the distribution chart, Mesoblast ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mesoblast has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #999999 out of 947 companies for Net Margin %. This places Mesoblast in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mesoblast and its competitors. Mesoblast's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (MEOBF) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Mesoblast's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mesoblast (MEOBF), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
47GF Score

Get the complete analysis for MEOBF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price